AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

AbbVie and Calico Add Additional $1 Billion to 2014 Age-Related Disease Deal

Nearly four years after first forging a research collaboration, AbbVie and Calico, Google’s life science company, have extended that 10-year pact with another $1 billion pledge to develop therapies associated with age-related diseases, including neurodegeneration and cancer.

June 27, 2018

2 min read

Alex Keown

Business

AbbVie, Calibr Collaborate to Develop Next-Generation CAR-T Therapies for Solid Tumors

AbbVie is taking another shot at solid tumor treatments through a collaboration with Calibr.

June 25, 2018

2 min read

Alex Keown

Business

Top 5 Women Executives in the Biopharma Industry by Compensation

Not only are women generally underrepresented in the biopharma industry, but compared to many of the top male executives, underpaid. Here’s a closer look at the top five female executives by pay in the biopharma industry.

June 18, 2018

4 min read

Mark Terry

Drug Development

ObsEva Therapeutic Shows Reduction of Pain in Mid-Stage Endometriosis Trial

Ernest Loumaye, chief executive officer of Switzerland-based ObsEva, is excited about the potential opportunity to provide women a significant treatment for endometriosis-associated pain.

June 18, 2018

3 min read

Alex Keown

Business

Spotlight on Biopharma Fellowships: AbbVie and Keck Graduate Institute Launch PharmD Fellowship Program

AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.

June 13, 2018

3 min read

Mark Terry

Policy

AbbVie Responds to FDA Criticism Over Manufacturing Complaints

The U.S. Food and Drug Administration (FDA) recently reprimanded AbbVie for its processes for investigating reports of deaths associated with three of its drugs.

June 12, 2018

2 min read

Mark Terry

FDA

AbbVie and Roche’s Venclexta and Rituxan Combo Gets FDA Approval

The U.S. Food and Drug Administration (FDA) approved AbbVie and Roche’s combination of Venclexta in combination with Rituxan (rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion in patients who have received at least one previous therapy.

June 11, 2018

2 min read

Mark Terry

Drug Development

AbbVie’s Upadacitinib Looks Good in Arthritis Trial; Rova-T Looks Worse in Lung Cancer

AbbVie announced positive topline results from its SELECT-EARLY Phase III clinical trial in rheumatoid arthritis, but disappointed with Rova-T small-cell lung cancer therapy.

June 5, 2018

2 min read

Mark Terry